SGMTSagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fi…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive | ||
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says Sagimet Biosciences (SGMT) is making "good progress" in advancing denifanstat as a treatment for mod | MMT Newswires | |
 Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple. On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution […] | IInsider Monkey | |